Skip to main content

Table 9 Macroeconomic (ROI) for ranibizumab therapy for neovascular AMD using the societal cost perspective, combined-eye model

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Cost perspective Direct ophthalmic medical cost per patient Annual # of cases Total direct ophthalmic medical costs Net cost/case with direct ophthalmic costs 12-year financial gain
MARINA—costs off-setting the s direct ocular medical costs $79,056 178,000 $14.1 billion (−$282,517) $50.2 billion
MARINA GDP gain $79,056 178,000 $14.1 billion (−$165,842) $29.5 billion
  1. ROI return-on-investment referent to the direct medical costs associated with ranibizumab administration, GDP Gross Domestic Product, MARINA minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration (AMD)